Sign in to see private stats on your profile page — or add photo, interests, videos, mentoring, etc.

    Regis Kelly

    SchoolUCSF Chancellor/EVC/FAS
    DepartmentQB3 Quantitative Biosciences
    Address1700 4th Street
    San Francisco CA 94158
    vCardDownload vCard
      Other Positions
      TitleDirector, QB3 Institute

      Collapse Overview 
      Collapse Overview
      Dr. Regis B. Kelly is the Director of one of four California Institutes for Science and Innovation, created by the California Legislature to strengthen the academic foundation of its technology-based industries. QB3 is the only one of the four devoted exclusively to biology and to the life science industries. It is an innovation center made up of over 200 quantitative biologists at three northern California campuses (UCB, UCSC & UCSF) working at the interface of the physical and biological sciences and a team of professionals converting its discoveries into practical benefits for society.

      From 2000 to 2004, Dr. Kelly served as Executive Vice Chancellor at the University of California in San Francisco, where his major responsibility was the new Mission Bay campus.

      From 1995 to 2000, Dr. Kelly served as Chair of the Department of Biochemistry and Biophysics at UCSF; from 1988 to 1995, he was the Director of UCSF’s Cell Biology Graduate Program; and from 1992 to 2000, he was the Director of the Hormone Research Institute at UCSF. He has published extensively in the areas of cell and neurobiology.

      Dr. Kelly received his undergraduate degree in Physics from the University of Edinburgh in Scotland in 1961 and his Ph.D. in Biophysics from the California Institute of Technology in 1967. Following a post-doctoral fellowship at Stanford, Dr. Kelly was an instructor in the Department of Neurobiology at Harvard. He has served as Chairman of the Bay Area Scientific Innovation Consortium (BASIC) and on the Boards of the Malaysian Biotechnology Industry Advisory Board, the Scleroderma Research Foundation, Bridge Pharmaceuticals, the San Francisco Mayor’s Biotechnology Advisory Group and the San Francisco China Desk, among others. He is also a General Partner of Mission Bay Capital venture fund.

      Collapse ORNG Applications 
      Collapse In The News
      Collapse Awarded Grants
      Collapse Global Health

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Marie B, Sweeney ST, Poskanzer KE, Roos J, Kelly RB, Davis GW. Dap160/intersectin scaffolds the periactive zone to achieve high-fidelity endocytosis and normal synaptic growth. Neuron. 2004 Jul 22; 43(2):207-19. PMID: 15260957.
        View in: PubMed
      2. Jarousse N, Wilson JD, Arac D, Rizo J, Kelly RB. Endocytosis of synaptotagmin 1 is mediated by a novel, tryptophan-containing motif. Traffic. 2003 Jul; 4(7):468-78. PMID: 12795692.
        View in: PubMed
      3. Dasgupta S, Kelly RB. Internalization signals in synaptotagmin VII utilizing two independent pathways are masked by intramolecular inhibitions. J Cell Sci. 2003 Apr 1; 116(Pt 7):1327-37. PMID: 12615974.
        View in: PubMed
      4. Zamanian JL, Kelly RB. Intersectin 1L guanine nucleotide exchange activity is regulated by adjacent src homology 3 domains that are also involved in endocytosis. Mol Biol Cell. 2003 Apr; 14(4):1624-37. PMID: 12686614; PMCID: PMC153127.
      Regis's Networks
      Related Concepts
      Derived automatically from this person's publications.
      People in Profiles who have published with this person.
      Related Authors
      People who share related concepts with this person.
      Back to TOP